Compound News and Research

RSS

New peptide targets the root causes of recurring seizures

New study suggests that an experimental peptide developed at the Hebrew University may reduce recurring seizures and support brain function by targeting underlying oxidative stress and inflammation processes linked to epilepsy.

28 Jan 2026

KAIST proposes novel strategy for multifactorial Alzheimer's treatment

Conventional treatments of Alzheimer's disease, one of the most common forms of dementia, have been largely focused on targeting individual pathological features.

27 Jan 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Short-term oatmeal diet improves cholesterol and metabolic health markers

A short-term oat-based diet appears to be surprisingly effective at reducing the cholesterol level. This is indicated by a trial by the University of Bonn, which has now been published in the journal Nature Communications.

23 Jan 2026

Cigarette compound exposure drives sorafenib resistance in hepatocellular carcinoma

A research team led by Professor Yuan Li at Nanjing Medical University published a research paper entitled "A Cigarette Compound-Induced Tumor Microenvironment Promotes Sorafenib Resistance in Hepatocellular Carcinoma via the 14-3-3η-Modified Tumor-Associated Proteome" in the Chinese Medical Journal.

23 Jan 2026

New copper-based drug shows promise against antibiotic-resistant MRSA

A research team at the University of Arizona College of Medicine – Tucson is developing a drug that works in combination with copper to kill bacteria, including those that cause MRSA, a type of staph infection that is resistant to usual treatments.

22 Jan 2026

Newly discovered survival pathway explains stubborn EGFR-driven lung cancers

Scientists from A*STAR Institute of Molecular and Cell Biology (A*STAR IMCB) have identified why certain lung cancer cells become highly resistant to treatment after developing mutations in a key gene called EGFR (epidermal growth factor receptor).

21 Jan 2026

Mcgill researchers find unexpected chemical contaminants in human milk samples

An interdisciplinary team including researchers at McGill University has found a range of unexpected chemical contaminants in human milk samples from Canada and South Africa.

20 Jan 2026

New study exposes a targetable vulnerability in acute myeloid leukemia

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway involved in the body's inflammation response.

19 Jan 2026

New oral drug safely lowers triglycerides and other blood lipids in Phase 1 trial

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids.

16 Jan 2026

Sapio Sciences announces partner ecosystem for ELaiN, its third-generation AI lab notebook

Sapio Sciences, the science-aware™ AI lab informatics platform, today announced the availability of trusted, third-party scientific applications and platforms now integrated directly into Sapio ELaiN, its third-generation AI lab notebook.

From Sapio Sciences 16 Jan 2026

Gut bacteria compound during pregnancy protects offspring from fatty liver disease

Children born to mothers who consume a high-fat, high-sugar diet during pregnancy and breastfeeding face a higher risk of developing fatty liver disease later in life.

14 Jan 2026

Bacterial metabolite enhances immune checkpoint therapy against lung cancer

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made into a drug for testing in humans.

14 Jan 2026

New chemistry revives neurokinin-1 receptor as depression treatment target

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major depressive disorder.

14 Jan 2026

Cannabidiol could become a therapeutic tool for fetal alcohol spectrum disorder

Cannabidiol (CBD) could become a therapeutic tool to address some of the most frequent and disabling consequences of fetal alcohol spectrum disorder (FASD), a condition caused by alcohol exposure during pregnancy.

14 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026